Michael Patrick Boyle, M.D.

Headshot of Michael Patrick Boyle


Cystic Fibrosis, Lung Transplant, Pulmonary and Critical Care Medicine ...read more

Research Interests

CFTR Modulators; Cystic Fibrosis Clinical Trials; Difficult to Treat Infections in Cystic Fibrosis ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-3467
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Johns Hopkins Bayview Medical Center

Appointment Phone: 410-550-5864
4940 Eastern Avenue
Baltimore, MD 21224
Johns Hopkins Bayview Medical Center - Google Maps


Dr. Michael Boyle is an Adjunct Professor of Medicine at the Johns Hopkins University School of Medicine, and President and CEO of the U.S. Cystic Fibrosis Foundation. His areas of expertise include adult cystic fibrosis care and research.  Dr. Boyle founded and directed the Johns Hopkins Adult Cystic Fibrosis Program from 1999 to 2015 at the Johns Hopkins Cystic Fibrosis Center. Dr. Boyle completed all of his medical training at Johns Hopkins including fellowship in pulmonary and critical care medicine before joining the Johns Hopkins faculty in 1999. He is internationally known both for his clinical research in CFTR modulators and for his work to improve care for adults with cystic fibrosis.  While at Johns Hopkins he has received numerous honors including the American Lung Association’s George Comstock Career Achievement Award, American Federation of Clinical Research Achievement Award, “Patient’s Choice Award”, “Best Full-Time Faculty Teacher”, and “Best Doctors in America”.

...read more

Departments / Divisions

Centers & Institutes



  • MD; Johns Hopkins University School of Medicine (1991)


  • Internal Medicine; Johns Hopkins University School of Medicine (1994)


  • Pulmonary and Critical Care Medicine; Johns Hopkins University School of Medicine (1999)

Research & Publications

Research Summary

Dr. Boyle is internationally known for his clinical research in both CFTR modulators and difficult to treat lung infections.  He has been the principal investigator for international clinical trials of CFTR modulator therapies which resulted in approval of new therapies for individuals with cystic fibrosis.

Selected Publications

View all on PubMed

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 373:220-31, 2015. PMID: 25981758

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D. on behalf of the VX09-809-102 Study Group. Randomised Trial of Combined CFTR Corrector and Potentiator Therapy in F508del-CFTR Cystic Fibrosis. The Lancet – Respiratory Medicine. 2: 527-38, 2014. PMID: 24973281

Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association of Respiratory Tract Methicillin-Resistant Staphylococcus Aureus and Survival in Cystic Fibrosis. JAMA 303:2386-92, 2010. PMID: 20551409

Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent Methicillin-resistant Staphylococcus Aureus and Rate of FEV1 Decline in Cystic Fibrosis. Am J Respir Crit Care Med 178:814-821; 2008. PMID: 18669817

Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key Findings of the Cystic Fibrosis Foundation's U.S. Clinical Practice Benchmarking Project. BMJ Quality and Safety. 23:15-22, 2014. PMID: 24608546

Contact for Research Inquiries

1830 E. Monument Street, 5th floor
Division of Pulmonary and Critical Care Medicine
Baltimore, MD 21205 map

Activities & Honors


  • Best Doctors in America
  • Alpha Omega Alpha (AOA), Johns Hopkins Chapter, 2006

Professional Activities

  • Senior Vice President of Therapeutics Development, Cystic Fibrosis Foundation, 2015
  • President and CEO, Cystic Fibrosis Foundation, 2020
Is this you? Edit Profile
back to top button